TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01260727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-G DNA Vaccine
Description: PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-G DNA Vaccine
Description: PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-G DNA Vaccine
Description: PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-G DNA Vaccine
Description: PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR Vaccine
Description: MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR Vaccine
Description: MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR Vaccine
Description: MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR Vaccine
Description: MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PENNVAX-G Vaccine
Description: Sodium Chloride Injection USP, 0.9%

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PENNVAX-G Vaccine
Description: Sodium Chloride Injection USP, 0.9%

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MVA-CMDR Vaccine
Description: Sodium Chloride Injection USP, 0.9%

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MVA-CMDR Vaccine
Description: Sodium Chloride Injection USP, 0.9%
Study: NCT02367326

Intervention type: OTHER
Intervention: data collection
Description: data collection will be carried out by the investigator during a standard hospitalization of the patient
Study: NCT01219647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: subjects will participate in one of two forms of exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stretching
Description: subjects will particiopate in supervised stretching as described in arm description.
Study: NCT02018367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine, high resolution imaging
Description: 5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
Study: NCT04005651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POD L GF IOL
Description: Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symfony® IOL
Description: Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof® IOL
Description: Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
Study: NCT04658459

Intervention type: PROCEDURE
Intervention: Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis

Intervention type: PROCEDURE
Intervention: Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis
Study: NCT02221232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloraprep
Description: Apply topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZuraPrep Vehicle
Description: Apply topically.
Study: NCT02701088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracile and Mitomycin-C
Description: All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy
Description: SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
Study: NCT05659433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEUS-guided percutaneous biopsy
Description: A standard dose of SonoVue ultrasound contrast agent is injected prior to the biopsy, and the percutaneous biopsy is guided in real time, targeting the contrast-enhanced areas of the retroperitoneal tumors (viable, vascularized)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-mode US-guided percutaneous biopsy
Description: Standard of care (B-mode) ultrasound-guided percutaneous biopsy, without contrast enhancement
Study: NCT00993915

Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin, 10- 80 mg, once daily, 6 month treatment
Study: NCT00760396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subjects will

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subjects will

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subjects will

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-1027
Description: Subjects will
Study: NCT02119325

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25% fibre
Description: Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0% fibre
Description: Placebo is an energy matched powdered beverage
Study: NCT02279823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01 solution
Description: Investigational drug solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil Solution 5%
Description: FDA approved marketed product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Vehicle solution
Study: NCT02267356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00631189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 5mg oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 5mg oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 40mg oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10mg oral
Study: NCT00874770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 3 mg, Daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 10 mg, Daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, Daily, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, 0 mg, Daily 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, subcutaneous, 180 µg, Weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, subcutaneous, 180 µg, Weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a
Description: Syringe, subcutaneous, 180 µg, Weekly, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha-2a
Description: Syringe, subcutaneous, 180 µg, Weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
Study: NCT03575390

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate
Description: Pomegranate extract 500mg
Study: NCT01129726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transillumination-guided Fiberoptic Intubation
Description: Light guided, Non-invasive
Study: NCT01659372

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Study: NCT01956656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lotus leaf mouthwash
Description: Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
Study: NCT02955576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle HA patch
Description: The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patch
Description: The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.
Study: NCT00973154

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 50mg per day of prednisone orally for 7 days versus placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 50mg per day of prednisone orally for 7 days versus placebo
Study: NCT04873414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma treatment
Description: Convalescent Plasma collected from patients who recover from COVID-19 and have been discharged from the hospital for at least 14 days.
Study: NCT02785497

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: will be turn on the equipment, positioning the patient but no put intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: This group will receive electrostimulation
Study: NCT01569360

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corset
Description: the patients are assigned the use of a custome made corset during daytime
Study: NCT03758521

Intervention type: DEVICE
Intervention: Transcranial magnetic stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.

Intervention type: DEVICE
Intervention: Magnetic resonance imaging (MRI)
Description: These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.

Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.

Intervention type: PROCEDURE
Intervention: Bio-specimen Collection
Description: Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.

Intervention type: PROCEDURE
Intervention: Bio-specimen Collection
Description: Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.

Intervention type: PROCEDURE
Intervention: Bio-specimen Collection
Description: Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
Study: NCT00588536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Thioguanine
Description: 6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: 5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
Study: NCT01047696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plancha
Description: locally developed chimney stove
Study: NCT04876534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 20 Mg/mL Intravenous Solution
Description: Intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MethylPREDNISolone Injectable Solution
Description: Intravenous administration
Study: NCT00725634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-299
Description: AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-299 + erlotinib
Description: AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
Study: NCT04636866

Intervention type: OTHER
Intervention: NO intervention
Description: NO intervention

Intervention type: OTHER
Intervention: NO intervention
Description: NO intervention
Study: NCT00307528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Five different formulations, each administered to one Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Five different formulations, each administered to one Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Five different formulations, each administered to one Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Five different formulations, each administered to one Group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK513026
Description: Two-dose intramuscular injection. Five different formulations, each administered to one Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23™
Description: Single dose intramuscular injection.
Study: NCT03948217

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Lighting regimen
Description: Circadian lighting regimen with one major fluctuation, high light intensity and color

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Lighting regimen
Description: Circadian lighting regimen with one major fluctuation, high light intensity and color
Study: NCT00867113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: imatinib mesylate was supplied in 100 and 400 mg tablets
Study: NCT01970488

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABP 501
Description: Administered by subcutaneous injection
Study: NCT03326895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left-sided colon resection
Description: Left-sided colon resection with powered stapler
Study: NCT00364871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone and bupropion SR
Description: naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Study: NCT04032769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MODS (MOdified Diagnostic Strategy)
Description: Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)
Study: NCT03838354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 2.5 mg po biw, every four weeks for one cycle. It will be given three cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 5 mg po biw, every four weeks for one cycle. It will be given three cycles.
Study: NCT04379336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG)
Description: BCG vaccine will be given intradermally in the upper arm after randomization.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo injection will be given intradermally in the upper arm after randomization.
Study: NCT02177890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham vagal nerve stimulation
Study: NCT04393025

Intervention type: DEVICE
Group type: OTHER
Intervention: Intracranial Stenting by Intracranial Stent Device
Description: Large Intracranial Vessels with ICSD underwent catheter lab and IC stent is inserted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimum medical treatment
Description: Optimum Medical treatment
Study: NCT03178708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A amantadine sulfate
Description: infusion solution for slowly intravenous application 3 hours preoperative

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group B ringer lactate
Description: infusion solution for intravenous application 3 hours preoperative
Study: NCT04347850

Intervention type: OTHER
Intervention: blood sample
Description: Collection

Intervention type: OTHER
Intervention: blood sample
Description: Collection

Intervention type: OTHER
Intervention: blood sample
Description: Collection
Study: NCT02068365

Intervention type: DRUG
Group type: OTHER
Intervention: Pegyinterferon-alfa-2a
Description: Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks